CN102373215A - 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 - Google Patents
具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 Download PDFInfo
- Publication number
- CN102373215A CN102373215A CN2011102858348A CN201110285834A CN102373215A CN 102373215 A CN102373215 A CN 102373215A CN 2011102858348 A CN2011102858348 A CN 2011102858348A CN 201110285834 A CN201110285834 A CN 201110285834A CN 102373215 A CN102373215 A CN 102373215A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- sequence
- cell
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 95
- 108091007433 antigens Proteins 0.000 title claims abstract description 95
- 102000036639 antigens Human genes 0.000 title claims abstract description 95
- 239000012636 effector Substances 0.000 title abstract description 51
- 108010087819 Fc receptors Proteins 0.000 title abstract description 19
- 102000009109 Fc receptors Human genes 0.000 title abstract description 19
- 230000001965 increasing effect Effects 0.000 title abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 136
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 36
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 181
- 229920001184 polypeptide Polymers 0.000 claims description 177
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 177
- 150000002482 oligosaccharides Chemical class 0.000 claims description 85
- 229920001542 oligosaccharide Polymers 0.000 claims description 83
- 108091033319 polynucleotide Proteins 0.000 claims description 77
- 102000040430 polynucleotide Human genes 0.000 claims description 77
- 239000002157 polynucleotide Substances 0.000 claims description 77
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 60
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 60
- 230000004927 fusion Effects 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 39
- 230000004048 modification Effects 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 22
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 11
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 11
- 102000004357 Transferases Human genes 0.000 claims description 7
- 108090000992 Transferases Proteins 0.000 claims description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 7
- 238000011282 treatment Methods 0.000 abstract description 41
- 230000013595 glycosylation Effects 0.000 abstract description 37
- 238000006206 glycosylation reaction Methods 0.000 abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 21
- 230000001225 therapeutic effect Effects 0.000 abstract description 20
- 239000013598 vector Substances 0.000 abstract description 2
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 263
- 230000006870 function Effects 0.000 description 48
- 241000282414 Homo sapiens Species 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 42
- 210000003719 b-lymphocyte Anatomy 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 38
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 36
- 125000003275 alpha amino acid group Chemical group 0.000 description 35
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 34
- 230000000295 complement effect Effects 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 230000006907 apoptotic process Effects 0.000 description 29
- 230000003013 cytotoxicity Effects 0.000 description 29
- 231100000135 cytotoxicity Toxicity 0.000 description 29
- 230000033581 fucosylation Effects 0.000 description 28
- 239000013604 expression vector Substances 0.000 description 27
- 238000011534 incubation Methods 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 27
- 230000008859 change Effects 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 22
- 239000008280 blood Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000009466 transformation Effects 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 208000003950 B-cell lymphoma Diseases 0.000 description 17
- 229960004641 rituximab Drugs 0.000 description 17
- 230000008034 disappearance Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000000890 antigenic effect Effects 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 230000008521 reorganization Effects 0.000 description 13
- 239000003053 toxin Substances 0.000 description 13
- 231100000765 toxin Toxicity 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 241000699802 Cricetulus griseus Species 0.000 description 11
- 238000013016 damping Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 210000001672 ovary Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 10
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 238000006073 displacement reaction Methods 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 239000002596 immunotoxin Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005336 cracking Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 230000001131 transforming effect Effects 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000002637 immunotoxin Effects 0.000 description 7
- 229940051026 immunotoxin Drugs 0.000 description 7
- 231100000608 immunotoxin Toxicity 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002864 sequence alignment Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- -1 Xie Ansuan Chemical compound 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000013311 vegetables Nutrition 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 5
- 108010073807 IgG Receptors Proteins 0.000 description 5
- 102000009490 IgG Receptors Human genes 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000004041 dendritic cell maturation Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000011125 single therapy Methods 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000037914 B-cell disorder Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108700023372 Glycosyltransferases Proteins 0.000 description 4
- 102000051366 Glycosyltransferases Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108010039491 Ricin Proteins 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 101150108347 sdhB gene Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 4
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010019236 Fucosyltransferases Proteins 0.000 description 3
- 102000006471 Fucosyltransferases Human genes 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052738 indium Inorganic materials 0.000 description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 229940047431 recombinate Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000002512 suppressor factor Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000768494 Polymorphum Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011363 radioimmunotherapy Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003582 thrombocytopenic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 235000019263 trisodium citrate Nutrition 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DWHJJLTXBKSHJG-UHFFFAOYSA-N 5-hydroxy-2-methylpent-2-enoic acid Chemical compound OC(=O)C(C)=CCCO DWHJJLTXBKSHJG-UHFFFAOYSA-N 0.000 description 1
- NVWKYNBWYYJZTK-UHFFFAOYSA-N 8-(2,5-dioxopyrrolidin-1-yl)oxy-8-oxooctanoic acid Chemical class OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O NVWKYNBWYYJZTK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 208000008286 Aortic Arch Syndromes Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000532851 Exophthalmus Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 101150098499 III gene Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 101001059701 Spodoptera frugiperda Alpha-mannosidase 2 Proteins 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102220503491 Transmembrane protease serine 9_S30T_mutation Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229910001361 White metal Inorganic materials 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001905 anti-neuroblastoma Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical group O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026915 cervical aortic arch Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- JKNIOHXBRYZCTM-UHFFFAOYSA-N dimethyl hexanediimidate;hydrochloride Chemical compound Cl.COC(=N)CCCCC(=N)OC JKNIOHXBRYZCTM-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SQMPFRFYKISAHD-YFKPBYRVSA-N ethyl (2s)-2,5-diamino-5-oxopentanoate Chemical compound CCOC(=O)[C@@H](N)CCC(N)=O SQMPFRFYKISAHD-YFKPBYRVSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical class COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 150000002475 indoles Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 101150112970 up gene Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000010969 white metal Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01144—Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (2.4.1.144)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
Abstract
Description
Kabat | Chothia | AbM | |
VH CDR1 | 31-35 | 26-32 | 26-35 |
VH CDR2 | 50-65 | 52-58 | 50-58 |
VH CDR3 | 95-102 | 95-102 | 95-102 |
VL CDR1 | 24-34 | 26-32 | |
VL CDR2 | 50-56 | 50-52 | |
VL CDR3 | 89-97 | 91-96 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51709603P | 2003-11-05 | 2003-11-05 | |
US60/517,096 | 2003-11-05 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480039946.3A Division CN1902231B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102373215A true CN102373215A (zh) | 2012-03-14 |
CN102373215B CN102373215B (zh) | 2014-07-30 |
Family
ID=34572912
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510181109.4A Pending CN104829719A (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
CN200480039946.3A Active CN1902231B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
CN201110285834.8A Active CN102373215B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
CN201110285833.3A Active CN102373214B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510181109.4A Pending CN104829719A (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
CN200480039946.3A Active CN1902231B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110285833.3A Active CN102373214B (zh) | 2003-11-05 | 2004-11-05 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
Country Status (40)
Country | Link |
---|---|
US (7) | US9296820B2 (zh) |
EP (5) | EP2380910B1 (zh) |
JP (5) | JP4653109B2 (zh) |
KR (3) | KR101364858B1 (zh) |
CN (4) | CN104829719A (zh) |
AT (1) | ATE463513T1 (zh) |
AU (1) | AU2004287643C1 (zh) |
BE (1) | BE2016C008I2 (zh) |
BR (2) | BR122020013239B1 (zh) |
CA (1) | CA2544865C (zh) |
CR (1) | CR11848A (zh) |
CY (6) | CY1110301T1 (zh) |
DE (1) | DE602004026470D1 (zh) |
DK (5) | DK1692182T3 (zh) |
EA (4) | EA202091901A1 (zh) |
EC (2) | ECSP066603A (zh) |
ES (5) | ES2708095T3 (zh) |
FR (1) | FR15C0076I2 (zh) |
HK (4) | HK1100005A1 (zh) |
HR (5) | HRP20100303T1 (zh) |
HU (5) | HUE031632T2 (zh) |
IL (4) | IL175367A (zh) |
LT (4) | LT2380911T (zh) |
LU (2) | LU92632I2 (zh) |
MA (1) | MA31040B1 (zh) |
ME (3) | ME02332B (zh) |
MX (2) | MXPA06004836A (zh) |
NL (1) | NL300801I2 (zh) |
NO (5) | NO347530B1 (zh) |
NZ (2) | NZ547589A (zh) |
PL (5) | PL2380911T3 (zh) |
PT (5) | PT2348051T (zh) |
RS (5) | RS51334B (zh) |
SG (3) | SG10202008722QA (zh) |
SI (5) | SI2348051T1 (zh) |
TN (1) | TNSN06126A1 (zh) |
TR (2) | TR201903329T4 (zh) |
UA (1) | UA91823C2 (zh) |
WO (1) | WO2005044859A2 (zh) |
ZA (1) | ZA200604547B (zh) |
Families Citing this family (777)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2180007T4 (da) * | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
CA2897608C (en) | 2003-05-09 | 2018-07-31 | Duke University | Cd20-specific antibodies and methods employing same |
LT2380911T (lt) * | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
EP1781378A2 (en) * | 2004-07-22 | 2007-05-09 | Genentech, Inc. | Method of treating sjögren's syndrome |
US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
KR20070100228A (ko) | 2004-10-05 | 2007-10-10 | 제넨테크, 인크. | 혈관염의 치료 방법 |
PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
RU2007145509A (ru) * | 2005-05-09 | 2009-06-20 | Гликарт Биотехнологи Аг (Ch) | Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами |
KR20080046135A (ko) * | 2005-05-20 | 2008-05-26 | 제넨테크, 인크. | 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리 |
KR20080032065A (ko) * | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
JP2009501913A (ja) | 2005-07-21 | 2009-01-22 | ゲンマブ エー/エス | Fc受容体と結合する抗体原薬に関する効力アッセイ |
AU2012216702B2 (en) * | 2005-08-26 | 2014-12-04 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
CA2619298C (en) * | 2005-08-26 | 2017-07-04 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
EP2455100A3 (en) * | 2005-11-07 | 2012-11-07 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
WO2007126439A2 (en) | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
SI1973950T1 (sl) | 2006-01-05 | 2015-01-30 | Genentech, Inc. | Anti-EphB4 protitelesa in postopki njihove uporabe |
US8716033B2 (en) * | 2006-02-10 | 2014-05-06 | Life Technologies Corporation | Oligosaccharide modification and labeling of proteins |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
EA022780B1 (ru) * | 2006-04-05 | 2016-03-31 | Дзе Рокфеллер Юниверсити | СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG |
MX2008015132A (es) | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
AU2007256617A1 (en) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
NZ576032A (en) | 2006-10-12 | 2012-03-30 | Genentech Inc | Antibodies to lymphotoxin-alpha |
ES2636089T3 (es) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Anticuerpos e inmunoconjugados y usos para los mismos |
US8465741B2 (en) | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
AU2013202392B2 (en) * | 2006-12-20 | 2016-02-25 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
EP2120915B1 (en) | 2007-01-22 | 2011-09-28 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
EP2125013A4 (en) * | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | DLL4 SIGNALING INHIBITOR AND ITS USES |
CA2676766A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
SG10201503254TA (en) | 2007-05-14 | 2015-06-29 | Medimmune Llc | Methods of reducing eosinophil levels |
CN102838673B (zh) | 2007-06-25 | 2016-05-11 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
JP2010533495A (ja) | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用 |
PT2176296E (pt) | 2007-07-16 | 2012-05-14 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
AU2008295140A1 (en) * | 2007-09-05 | 2009-03-12 | F. Hoffmann-La Roche Ag | Combination therapy with type I and type II anti-CD20 antibodies |
AR068563A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
US20090110688A1 (en) * | 2007-10-24 | 2009-04-30 | Georg Fertig | Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
MX2010005108A (es) | 2007-11-07 | 2010-05-27 | Genentech Inc | Composiciones y metodos para el tratamiento de trastornos microbianos. |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
AU2008342956A1 (en) * | 2007-12-21 | 2009-07-09 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
UA101487C2 (en) * | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
MY157403A (en) | 2008-01-31 | 2016-06-15 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
EP2268310B1 (en) * | 2008-03-25 | 2016-07-20 | Roche Glycart AG | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
CA2718120A1 (en) * | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
MX2010011598A (es) * | 2008-04-22 | 2010-12-15 | Univ Rockefeller | Metodos para identificar compuestos anti-inflamatorios. |
WO2009134738A1 (en) * | 2008-04-29 | 2009-11-05 | Genentech, Inc. | Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody |
KR101054362B1 (ko) * | 2008-07-03 | 2011-08-05 | 재단법인 목암생명공학연구소 | 재조합 단백질의 푸코스 함량을 감소시키는 방법 |
EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
EP3524620A1 (en) | 2008-10-14 | 2019-08-14 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP6039183B2 (ja) | 2008-12-23 | 2016-12-07 | ジェネンテック, インコーポレイテッド | プロテインaに対する結合が変化した免疫グロブリン変異体 |
KR20130080871A (ko) | 2009-03-20 | 2013-07-15 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
CN104788564A (zh) * | 2009-03-25 | 2015-07-22 | 健泰科生物技术公司 | 抗-fgfr3抗体及其使用方法 |
CA2753988C (en) | 2009-03-25 | 2017-04-25 | Genentech, Inc. | Novel anti-.alpha.5.beta. integrin antibodies and uses thereof |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
SG177727A1 (en) | 2009-07-24 | 2012-02-28 | Hoffmann La Roche | Stirrer system |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
EP2459591B1 (en) | 2009-07-31 | 2014-08-20 | Genentech, Inc. | Inhibition of tumor metastasis using anti-g-csf-antibodies |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
JP2013501741A (ja) | 2009-08-14 | 2013-01-17 | ロシュ グリクアート アーゲー | アフコシル化cd20抗体とフルダラビン及び/又はミトキサントロンの併用療法 |
GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
JP5887270B2 (ja) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | 突然変異体smoothenedおよびその使用方法 |
AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
AR078716A1 (es) | 2009-10-22 | 2011-11-30 | Genentech Inc | Anticuerpos antihepsina y metodos para su uso |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
SI2496601T1 (sl) | 2009-11-05 | 2017-09-29 | F. Hoffmann-La Roche Ag | Tehnike in sestavek za sekrecijo heterolognih polipeptidov |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
AR078377A1 (es) | 2009-12-11 | 2011-11-02 | Genentech Inc | Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso |
SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
EP2516465B1 (en) | 2009-12-23 | 2016-05-18 | F.Hoffmann-La Roche Ag | Anti-bv8 antibodies and uses thereof |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
RU2577702C2 (ru) | 2010-02-11 | 2016-03-20 | Ф.Хоффманн-Ля Рош Аг | 3d-facs-анализ-adcc nk-клеток |
SI2536748T1 (sl) | 2010-02-18 | 2014-12-31 | Genentech, Inc. | Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka |
EP2550295A1 (en) | 2010-03-24 | 2013-01-30 | F. Hoffmann-La Roche AG | Anti-lrp6 antibodies |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
RU2585489C2 (ru) | 2010-04-27 | 2016-05-27 | Рош Гликарт Аг | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR |
AU2011250970B2 (en) | 2010-05-10 | 2016-12-15 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
SG185430A1 (en) | 2010-06-03 | 2012-12-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011159980A1 (en) | 2010-06-18 | 2011-12-22 | Genentech, Inc. | Anti-axl antibodies and methods of use |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
PL2591006T3 (pl) | 2010-07-09 | 2019-10-31 | Bioverativ Therapeutics Inc | Przetwarzalne cząsteczki jednołańcuchowe i polipeptydy wytworzone przy ich zastosowaniu |
CN103097418A (zh) | 2010-07-09 | 2013-05-08 | 霍夫曼-拉罗奇有限公司 | 抗神经毡蛋白抗体及使用方法 |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409989A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
FR2962908A1 (fr) | 2010-07-20 | 2012-01-27 | Lfb Biotechnologies | Formulation d'anticorps anti-cd20 |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
KR20130045914A (ko) | 2010-08-03 | 2013-05-06 | 에프. 호프만-라 로슈 아게 | 만성 림프구성 백혈병(cll) 생체지표 |
BR112013002532A2 (pt) | 2010-08-05 | 2016-05-31 | Hoffmann La Roche | proteína de fusão de citocina anti-viral do anticorpo anti-mhc |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
TW201209063A (en) | 2010-08-13 | 2012-03-01 | Roche Glycart Ag | Anti-tenascin-C A2 antibodies and methods of use |
BR112013003361B8 (pt) | 2010-08-13 | 2022-01-25 | Roche Glycart Ag | Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
TW201208703A (en) | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CA2805054A1 (en) | 2010-08-25 | 2012-03-01 | F. Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
US20120089541A1 (en) | 2010-08-31 | 2012-04-12 | Genentech, Inc. | Biomarkers and methods of treatment |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
DK2625197T3 (en) | 2010-10-05 | 2016-10-03 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
CN104998254A (zh) | 2010-11-08 | 2015-10-28 | 基因技术公司 | 皮下施用的抗-il-6受体抗体 |
SG190682A1 (en) | 2010-11-10 | 2013-07-31 | Genentech Inc | Methods and compositions for neural disease immunotherapy |
EP2646470B1 (en) | 2010-11-30 | 2017-03-01 | F. Hoffmann-La Roche AG | Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier |
MX2013006739A (es) | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. |
US20120156194A1 (en) | 2010-12-16 | 2012-06-21 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
UA115641C2 (uk) | 2010-12-20 | 2017-11-27 | Дженентек, Інк. | Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить |
US20120195910A1 (en) | 2010-12-22 | 2012-08-02 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
JP2014511147A (ja) | 2011-02-10 | 2014-05-12 | ロシュ グリクアート アーゲー | 改善された免疫療法 |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
BR112013024717A2 (pt) | 2011-04-07 | 2017-08-08 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
MY175338A (en) | 2011-05-16 | 2020-06-19 | Genentech Inc | Fgfr1 agonists and methods of use |
AR086924A1 (es) | 2011-06-15 | 2014-01-29 | Hoffmann La Roche | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
FR2976811A1 (fr) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
AR086982A1 (es) | 2011-06-22 | 2014-02-05 | Hoffmann La Roche | Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i |
CA2835242A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
MX2014001736A (es) | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
US9309306B2 (en) | 2011-08-23 | 2016-04-12 | Roche Glycart Ag | Anti-MCSP antibodies |
MX356947B (es) | 2011-08-23 | 2018-06-20 | Roche Glycart Ag | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2846083A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
WO2013043715A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
RU2014114119A (ru) | 2011-09-23 | 2015-10-27 | Рош Гликарт Аг | Биспецифические анти-egfr/анти igf-1r-антитела |
CN113061993A (zh) | 2011-09-30 | 2021-07-02 | 中外制药株式会社 | 离子浓度依赖性结合分子文库 |
WO2013044298A1 (en) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Antibodies against tl1a and uses thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
SG11201401287SA (en) | 2011-10-05 | 2014-05-29 | Genentech Inc | Methods of treating liver conditions using notch2 antagonists |
ES2687951T3 (es) | 2011-10-14 | 2018-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HtrA1 y procedimientos de uso |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
TW201325613A (zh) | 2011-10-28 | 2013-07-01 | Genentech Inc | 治療黑色素瘤之治療組合及方法 |
EP2771351B1 (en) | 2011-10-28 | 2017-06-14 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
RU2014124842A (ru) | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | Очистка анти-с-мет антител |
US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
US9963511B2 (en) | 2011-12-22 | 2018-05-08 | Hoffmann-La Roche Inc. | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
SG11201403445YA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Full length antibody display system for eukaryotic cells and its use |
EP2794651B1 (en) | 2011-12-22 | 2022-09-21 | F. Hoffmann-La Roche AG | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
SG10201601747XA (en) | 2012-01-18 | 2016-04-28 | Genentech Inc | Anti-LRP5 Antibodies And Methods Of Use |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
JP6545959B2 (ja) | 2012-02-11 | 2019-07-17 | ジェネンテック, インコーポレイテッド | Rスポンジン転位およびその使用方法 |
ES2676031T3 (es) | 2012-02-15 | 2018-07-16 | F. Hoffmann-La Roche Ag | Cromatografía de afinidad basada en el receptor Fc |
BR112014024017A8 (pt) | 2012-03-27 | 2017-07-25 | Genentech Inc | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
CN104470544B (zh) | 2012-05-01 | 2018-01-12 | 基因泰克公司 | 抗pmel17抗体和免疫缀合物 |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
US20130309226A1 (en) | 2012-05-18 | 2013-11-21 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
US20150353639A1 (en) | 2012-05-21 | 2015-12-10 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
RU2625771C2 (ru) | 2012-05-23 | 2017-07-18 | Дженентек, Инк. | Способ отбора терапевтических средств |
TW201410706A (zh) | 2012-06-15 | 2014-03-16 | Genentech Inc | 抗-pcsk9抗體、調配物、劑量及使用方法 |
EP2863954A1 (en) | 2012-06-21 | 2015-04-29 | Indiana University Research and Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
HUE029435T2 (en) | 2012-07-04 | 2017-02-28 | Hoffmann La Roche | Anti-theophylline antibodies and methods of their application |
KR20150030755A (ko) | 2012-07-04 | 2015-03-20 | 에프. 호프만-라 로슈 아게 | 항-바이오틴 항체 및 사용 방법 |
CA3188124A1 (en) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
EP2869847B1 (en) | 2012-07-09 | 2017-12-06 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
AR091700A1 (es) | 2012-07-09 | 2015-02-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd79b |
CA2874904A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
MX365382B (es) | 2012-08-07 | 2019-05-31 | Roche Glycart Ag | Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer. |
US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
AU2013305827A1 (en) | 2012-08-21 | 2015-03-05 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
RS58928B1 (sr) | 2012-08-29 | 2019-08-30 | Hoffmann La Roche | Transporter za krvno-moždanu barijeru |
EP3919079A1 (en) | 2012-09-07 | 2021-12-08 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
WO2014056783A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
SG11201502538TA (en) | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
CA2890669A1 (en) | 2012-11-13 | 2014-05-22 | Genetech, Inc. | Anti-hemagglutinin antibodies and methods of use |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
EP3514175A1 (fr) | 2012-12-17 | 2019-07-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
CN104884474A (zh) | 2012-12-21 | 2015-09-02 | 弗·哈夫曼-拉罗切有限公司 | 包含i类mhc的二硫键连接多价多功能蛋白质 |
US20140194368A1 (en) * | 2013-01-04 | 2014-07-10 | Beech Tree Labs, Inc. | Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70) |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
RU2519546C1 (ru) * | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
CN105531289B (zh) | 2013-02-01 | 2019-02-22 | 树突细胞生物科技有限公司 | 抗cd83抗体及其用途 |
EP4219552A3 (en) | 2013-02-07 | 2023-09-13 | CSL Ltd. | Il-11r binding proteins and uses thereof |
EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
DK2961771T3 (da) | 2013-02-26 | 2020-03-02 | Roche Glycart Ag | Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA |
US20140242083A1 (en) | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Anti-mcsp antibodies |
BR112015021423A2 (pt) | 2013-03-06 | 2017-07-18 | Genentech Inc | métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão |
AU2014248886B2 (en) * | 2013-03-12 | 2019-06-27 | University Of Utah Research Foundation | Compositions and methods for inducing apoptosis |
AR095396A1 (es) * | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones de anticuerpo |
AU2014239903A1 (en) | 2013-03-14 | 2015-09-17 | Genentech, Inc. | Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
BR112015022019A2 (pt) | 2013-03-14 | 2017-08-29 | Genentech Inc | Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer |
RU2015139054A (ru) | 2013-03-14 | 2017-04-19 | Дженентек, Инк. | Способы лечения рака и профилактики лекарственной резистентности рака |
SG10201706210WA (en) | 2013-03-15 | 2017-09-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of hepatic cancers |
WO2014144865A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
CN105143258B (zh) | 2013-03-15 | 2020-06-23 | Ac免疫有限公司 | 抗Tau抗体和使用方法 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2903587C (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
MY176706A (en) | 2013-03-15 | 2020-08-19 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
DK3460054T3 (da) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-syntetase-Fc-konjugater |
KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
JP2016528168A (ja) | 2013-04-29 | 2016-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合が無効となった抗IGF−1R抗体及び血管性眼疾患の処置におけるそれらの使用 |
EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
PL2992015T3 (pl) * | 2013-05-02 | 2019-01-31 | F.Hoffmann-La Roche Ag | Leczenie skojarzone niefukozylowanym przeciwciałem anty-CD20 z koniugatem przeciwciało anty-CD22-lek |
US20140356352A1 (en) * | 2013-05-02 | 2014-12-04 | Genentech, Inc. | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE |
CA2908743A1 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
NZ715201A (en) | 2013-08-01 | 2021-12-24 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
AR097685A1 (es) | 2013-09-17 | 2016-04-06 | Genentech Inc | Métodos de uso de anticuerpos anti-lgr5 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
RU2016117978A (ru) | 2013-10-11 | 2017-11-17 | Дженентек, Инк. | Ингибиторы nsp4 и способы их применения |
BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
JP6502931B2 (ja) | 2013-10-11 | 2019-04-17 | アメリカ合衆国 | Tem8抗体およびその使用 |
US20150147333A1 (en) | 2013-10-18 | 2015-05-28 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
JP6715767B2 (ja) | 2013-10-23 | 2020-07-01 | ジェネンテック, インコーポレイテッド | 好酸球性疾患の診断及び治療方法 |
SI3071597T1 (sl) | 2013-11-21 | 2020-11-30 | F. Hoffmann-La Roche Ag | Anti alfa-sinukleinska protitelesa in postopki uporabe |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
JP6549143B2 (ja) | 2013-12-09 | 2019-07-24 | アラコス インコーポレイテッド | 抗シグレック−8抗体およびその使用の方法 |
KR20160098328A (ko) | 2013-12-13 | 2016-08-18 | 제넨테크, 인크. | 항-cd33 항체 및 면역접합체 |
CA2933881A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
KR20240017102A (ko) | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
BR112016013849A2 (pt) | 2014-01-03 | 2017-10-10 | Hoffmann La Roche | conjugados de anticorpos biespecíficos antihapteno/antirreceptores da barreira hematoencefálica, seus usos, e formulação farmacêutica |
CA2930046A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ.ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
CN111057151B (zh) | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
MX2016008539A (es) | 2014-01-15 | 2016-09-26 | Hoffmann La Roche | Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas. |
KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP2017505305A (ja) | 2014-01-24 | 2017-02-16 | ジェネンテック, インコーポレイテッド | 抗steap1抗体及びイムノコンジュゲートを使用する方法 |
JP6736467B2 (ja) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | 平滑化変異体及びその使用方法 |
AU2015214058B2 (en) | 2014-02-08 | 2020-07-09 | Genentech, Inc. | Methods of treating Alzheimer's Disease |
PL3102230T3 (pl) | 2014-02-08 | 2021-11-15 | F.Hoffmann-La Roche Ag | Sposoby leczenia choroby Alzheimera |
MX2016010433A (es) | 2014-02-12 | 2016-09-22 | Genentech Inc | Anticuerpos anti-jagged1 y metodos de uso. |
UA117608C2 (uk) | 2014-02-21 | 2018-08-27 | Дженентек, Інк. | Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла |
JP6825909B2 (ja) | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | シグレック−8関連疾患を処置するための方法および組成物 |
US10435694B2 (en) | 2014-03-14 | 2019-10-08 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
JP2017516458A (ja) | 2014-03-24 | 2017-06-22 | ジェネンテック, インコーポレイテッド | c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関 |
EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
PT3126394T (pt) | 2014-03-31 | 2019-12-19 | Hoffmann La Roche | Anticorpos anti-ox40 e métodos de utilização |
EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
BR112016027222A2 (pt) | 2014-05-22 | 2018-01-30 | Genentech Inc | anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer |
KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
EP3149037A4 (en) | 2014-05-27 | 2018-01-10 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
KR20170005142A (ko) | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗TNFα糖操作抗体群およびその使用 |
ES2905777T3 (es) | 2014-05-30 | 2022-04-12 | Shanghai Henlius Biotech Inc | Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR) |
KR20170010785A (ko) | 2014-06-11 | 2017-02-01 | 제넨테크, 인크. | 항-lgr5 항체 및 이의 용도 |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
RU2705299C2 (ru) | 2014-06-26 | 2019-11-06 | Ф. Хоффманн-Ля Рош Аг | Антитела против 5-бром-2'-дезоксиуридина и способы применения |
SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
MA50584A (fr) | 2014-08-04 | 2020-09-16 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
CA2959141A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
TWI745275B (zh) | 2014-09-08 | 2021-11-11 | 中央研究院 | 使用醣脂激活人類iNKT細胞 |
CN106687481B (zh) * | 2014-09-10 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 半乳糖改造的免疫球蛋白1抗体 |
SI3191135T1 (sl) | 2014-09-12 | 2021-01-29 | Genentech, Inc. | Anti-HER2 protitelesa in imunokonjugati |
CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
CN106794247B (zh) | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
BR112017004953A2 (pt) | 2014-09-17 | 2017-12-05 | Genentech Inc | imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula |
CA3069221C (en) | 2014-09-23 | 2023-04-04 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
CA2965170A1 (en) | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
EP3223865A4 (en) | 2014-10-31 | 2018-10-03 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
US20160160290A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
EP3215850B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Assays for detecting t cell immune subsets and methods of use thereof |
RU2017119185A (ru) | 2014-11-05 | 2018-12-05 | Дженентек, Инк. | Антитела против fgfr2/3 и способы их применения |
CN107074966A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体 |
US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
PL3215528T3 (pl) | 2014-11-06 | 2020-01-31 | F.Hoffmann-La Roche Ag | Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
CN107105632A (zh) | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 肾病动物模型及其治疗剂 |
MX2017006250A (es) | 2014-11-14 | 2017-11-17 | Hoffmann La Roche | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf. |
EP3875481A1 (en) | 2014-11-14 | 2021-09-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
AU2015350242A1 (en) | 2014-11-17 | 2017-06-29 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
JP6859259B2 (ja) | 2014-11-19 | 2021-04-14 | ジェネンテック, インコーポレイテッド | BACElに対する抗体及び神経疾患免疫療法のためのその使用 |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
CA2966566C (en) | 2014-11-20 | 2024-03-19 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
HUE045216T2 (hu) | 2014-12-05 | 2019-12-30 | Hoffmann La Roche | Anti-CD79B antitestek és alkalmazási eljárások |
SG11201703750XA (en) | 2014-12-10 | 2017-06-29 | Genentech Inc | Blood brain barrier receptor antibodies and methods of use |
EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
EP3760644A1 (en) | 2015-01-16 | 2021-01-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2016117346A1 (en) | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CA2975875A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
KR20170140180A (ko) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도 |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
US10562960B2 (en) | 2015-03-20 | 2020-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to gp120 and their use |
PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
PT3273992T (pt) | 2015-03-23 | 2020-08-21 | Jounce Therapeutics Inc | Anticorpos para icos |
KR20170132793A (ko) | 2015-04-03 | 2017-12-04 | 유레카 쎄라퓨틱스, 인코포레이티드 | Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도 |
CN107810197B (zh) | 2015-04-24 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 鉴定包含结合多肽的细菌的方法 |
EP3290197B1 (en) * | 2015-04-30 | 2019-04-24 | FUJIFILM Corporation | Decorative sheet |
EP3288981A1 (en) | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
CN107592812A (zh) | 2015-05-11 | 2018-01-16 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
IL255312B (en) | 2015-05-12 | 2022-08-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist |
EP3708681A1 (en) | 2015-05-29 | 2020-09-16 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
JP2018520658A (ja) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | ヒト化抗エボラウイルス糖タンパク質抗体及びその使用 |
EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
NZ738389A (en) | 2015-06-04 | 2019-02-22 | Ospedale San Raffaele Srl | Inhibitor of igfbp3/tmem219 axis and diabetes |
WO2016193496A1 (en) | 2015-06-04 | 2016-12-08 | Ospedale San Raffaele Srl | Igfbp3 and uses thereof |
PE20180317A1 (es) | 2015-06-05 | 2018-02-09 | Genentech Inc | Anticuerpos anti-tau y metodos de uso |
EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
CN107810011A (zh) | 2015-06-08 | 2018-03-16 | 豪夫迈·罗氏有限公司 | 使用抗ox40抗体治疗癌症的方法 |
TW201709934A (zh) | 2015-06-15 | 2017-03-16 | 建南德克公司 | 抗體及免疫結合物 |
CN107849145B (zh) | 2015-06-16 | 2021-10-26 | 基因泰克公司 | 抗cd3抗体及其使用方法 |
IL256079B2 (en) | 2015-06-16 | 2024-01-01 | Genentech Inc | Human antibodies with improved affinity to FCRH5 - and methods of use |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
CA2987797A1 (en) | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
KR20180012859A (ko) | 2015-06-17 | 2018-02-06 | 제넨테크, 인크. | 항-her2 항체 및 이용 방법 |
RU2020124105A (ru) | 2015-06-24 | 2020-09-18 | Ф. Хоффманн-Ля Рош Аг | Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью |
EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
BR112017027614A2 (pt) * | 2015-06-24 | 2018-08-28 | Hoffmann La Roche | anticorpos e método de direcionamento da terapia para um câncer. |
CA2990305A1 (en) | 2015-06-26 | 2016-12-29 | Mab Discovery Gmbh | Monoclonal anti-il-1racp antibodies |
EP3514174B1 (en) | 2015-06-29 | 2021-03-31 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
MX2017016645A (es) | 2015-06-29 | 2018-11-09 | Genentech Inc | Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos. |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
EP3341415B1 (en) | 2015-08-28 | 2021-03-24 | H. Hoffnabb-La Roche Ag | Anti-hypusine antibodies and uses thereof |
EP3353206A1 (en) | 2015-09-22 | 2018-08-01 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
BR112018005737A2 (pt) | 2015-09-23 | 2018-10-09 | Genentech Inc | anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína |
KR20180083313A (ko) | 2015-09-24 | 2018-07-20 | 에이비비트로, 엘엘씨 | Hiv 항체 조성물 및 사용 방법 |
RU2732591C2 (ru) | 2015-09-25 | 2020-09-21 | Дженентек, Инк. | Анти-tigit антитела и способы применения |
US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
CR20180149A (es) | 2015-10-02 | 2018-04-05 | Hoffmann La Roche | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso |
CN115746143A (zh) | 2015-10-02 | 2023-03-07 | 豪夫迈·罗氏有限公司 | 对共刺激性tnf受体特异性的双特异性抗体 |
JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
SI3356411T1 (sl) | 2015-10-02 | 2021-09-30 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, specifična za PD1 in TIM3 |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
AU2016335750B2 (en) | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
EP4015533A1 (en) | 2015-10-29 | 2022-06-22 | F. Hoffmann-La Roche AG | Anti-variant fc-region antibodies and methods of use |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
KR102162324B1 (ko) | 2015-10-30 | 2020-10-07 | 제넨테크, 인크. | 항-HtrA1 항체 및 이의 사용 방법 |
US11236152B2 (en) | 2015-11-03 | 2022-02-01 | The United States of America, as represented by the Sectetary, Department of Health and Human Services | Neutralizing antibodies to HIV-1 GP41 and their use |
WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
SG10201913538VA (en) | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CN115920030A (zh) | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
SG10201709415WA (en) | 2015-12-18 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
US20190016791A1 (en) | 2016-01-20 | 2019-01-17 | Genentech, Inc. | High dose treatments for alzheimer's disease |
CN109071625A (zh) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | 平滑化突变体和其使用方法 |
AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
WO2017148880A1 (en) | 2016-03-01 | 2017-09-08 | F. Hoffmann-La Roche Ag | Obinutuzumab variants having altered cell death induction |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
TWI759287B (zh) | 2016-03-15 | 2022-04-01 | 日商中外製藥股份有限公司 | 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法 |
LT3433280T (lt) | 2016-03-22 | 2023-07-10 | F. Hoffmann-La Roche Ag | Proteazės aktyvuojamos t ląstelei bispecifinės molekulės |
JP6943872B2 (ja) | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 多重全抗体及び抗体複合体化薬物定量化アッセイ |
PE20190126A1 (es) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos de uso de las mismas |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
CA3021086C (en) | 2016-04-15 | 2023-10-17 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
CA3019921A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
CN109154027A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
UA123323C2 (uk) | 2016-05-02 | 2021-03-17 | Ф. Хоффманн-Ля Рош Аг | Димерний злитий поліпептид |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
WO2017194442A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
TW202208441A (zh) | 2016-05-13 | 2022-03-01 | 美商拜奧亞特拉公司 | 抗-ror2抗體、抗體片段、其免疫結合物及其用途 |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
EP3257866A1 (en) | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
EP3475298A1 (en) | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Anti-polyubiquitin multispecific antibodies |
MX2018015414A (es) * | 2016-06-30 | 2019-08-01 | Hoffmann La Roche | Terapia de célula t adoptiva mejorada. |
EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
AU2017301887A1 (en) | 2016-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies against anti-CD19 antibodies |
CN109415444B (zh) | 2016-07-29 | 2024-03-01 | 中外制药株式会社 | 显示增加的备选fviii辅因子功能活性的双特异性抗体 |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CN116731197A (zh) | 2016-09-19 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 基于补体因子的亲和层析 |
FI3528838T3 (fi) | 2016-09-23 | 2023-10-02 | Hoffmann La Roche | IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi |
PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
KR20190072528A (ko) | 2016-10-06 | 2019-06-25 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
CA3039992A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
EP4015532A1 (en) | 2016-11-21 | 2022-06-22 | cureab GmbH | Anti-gp73 antibodies and immunoconjugates |
KR102587130B1 (ko) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
WO2018111890A1 (en) | 2016-12-12 | 2018-06-21 | Genentech, Inc. | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
EP3554542A1 (en) | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
CR20190309A (es) | 2017-01-03 | 2019-08-21 | Hoffmann La Roche | Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb |
US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
TW201831517A (zh) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
CR20190387A (es) | 2017-02-10 | 2019-09-25 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
TW201837467A (zh) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | 用於癌症之診斷及治療方法 |
JP7227151B2 (ja) | 2017-03-22 | 2023-02-21 | ジェネンテック, インコーポレイテッド | 眼障害の治療のために最適化された抗体組成物 |
EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
CN110382542B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
CN110573528B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
SG11201908787WA (en) | 2017-04-04 | 2019-10-30 | Hoffmann La Roche | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
IL268527B2 (en) | 2017-04-05 | 2024-03-01 | Hoffmann La Roche | Bispecific antibodies bind to PD1 and LAG3 specifically |
MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
EP3610042A1 (en) | 2017-04-14 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
AU2018256435A1 (en) | 2017-04-20 | 2019-11-07 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
MA49131A (fr) | 2017-04-21 | 2020-03-25 | Hoffmann La Roche | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie |
KR102663596B1 (ko) | 2017-04-26 | 2024-05-10 | 유레카 쎄라퓨틱스, 인코포레이티드 | 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도 |
MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
CN110831628A (zh) | 2017-05-05 | 2020-02-21 | 爱乐科斯公司 | 用于治疗过敏性眼病的方法和组合物 |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
EP3630829A1 (en) | 2017-06-02 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
TWI823859B (zh) | 2017-07-21 | 2023-12-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
EP3658584A1 (en) | 2017-07-26 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
MY202382A (en) | 2017-08-08 | 2024-04-24 | Hoffmann La Roche | Obinutuzumab treatment of a dlbcl patient subgroup |
CN107881160A (zh) | 2017-08-11 | 2018-04-06 | 百奥泰生物科技(广州)有限公司 | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
EP3456738A1 (en) * | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
EP3684413A1 (en) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
AU2018345539A1 (en) | 2017-10-03 | 2020-04-16 | Editas Medicine, Inc. | HPV-specific binding molecules |
US11912754B2 (en) | 2017-10-12 | 2024-02-27 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
US20200299398A1 (en) | 2017-10-19 | 2020-09-24 | F. Hoffmann-La Roche Ag | Treatment of cd20-positive b-cell lymphoma with obituzumab |
MX2020004573A (es) | 2017-11-01 | 2020-09-25 | Hoffmann La Roche | Terapia de combinacion con agonistas de ox40 dirigidos. |
EP3703746A1 (en) | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Novel tnf family ligand trimer-containing antigen binding molecules |
PE20210844A1 (es) | 2017-11-01 | 2021-05-10 | Hoffmann La Roche | Contorsbodies 2 + biespecificos |
MX2020004243A (es) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b. |
EP3707510B1 (en) | 2017-11-06 | 2024-06-26 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
EP3717516A1 (en) | 2017-12-01 | 2020-10-07 | Pfizer Inc | Anti-cxcr5 antibodies and compositions and uses thereof |
KR20200099135A (ko) | 2017-12-14 | 2020-08-21 | 에프. 호프만-라 로슈 아게 | Cea cd3 이중특이성 항체 및 pd-1 축 결합 길항제의 암 치료를 위한 투약 요법에서의 용도 |
CN112204048A (zh) | 2017-12-15 | 2021-01-08 | 朱诺治疗学股份有限公司 | 抗cct5结合分子及其使用方法 |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
KR20200103706A (ko) | 2017-12-22 | 2020-09-02 | 조운스 테라퓨틱스, 인크. | Lilrb2에 대한 항체 |
KR20200104333A (ko) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 단일-도메인 항체 및 이의 변이체 |
TW201930350A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對pd-l1之抗體及其變異體 |
US11976109B2 (en) | 2018-01-02 | 2024-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
BR112020013663A2 (pt) | 2018-01-05 | 2020-12-01 | Ac Immune Sa | moléculas de ligação ao tdp-43 dobrado incorretamente |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
EP3743437A1 (en) | 2018-01-26 | 2020-12-02 | F. Hoffmann-La Roche AG | Il-22 fc fusion proteins and methods of use |
RS63812B1 (sr) | 2018-01-26 | 2023-01-31 | Hoffmann La Roche | Il-22 fc kompozicije i postupci primene |
CN111601825B (zh) | 2018-02-01 | 2022-11-29 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
EP3749361A1 (en) | 2018-02-08 | 2020-12-16 | F. Hoffmann-La Roche AG | Bispecific antigen-binding molecules and methods of use |
KR20230142806A (ko) | 2018-02-09 | 2023-10-11 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
WO2019158645A1 (en) | 2018-02-14 | 2019-08-22 | Abba Therapeutics Ag | Anti-human pd-l2 antibodies |
EP3755713A1 (en) | 2018-02-21 | 2020-12-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2019165140A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
CA3092108A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
MX2020009512A (es) | 2018-03-13 | 2020-10-22 | Hoffmann La Roche | Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados. |
KR20200132913A (ko) | 2018-03-13 | 2020-11-25 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
WO2019174617A1 (en) | 2018-03-14 | 2019-09-19 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CN116327926A (zh) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
CA3092589A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
SG11202009284TA (en) | 2018-04-05 | 2020-10-29 | Juno Therapeutics Inc | T cell receptors and engineered cells expressing same |
EP3773913A1 (en) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
EP3774900A1 (en) | 2018-04-13 | 2021-02-17 | F. Hoffmann-La Roche AG | Her2-targeting antigen binding molecules comprising 4-1bbl |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
BR112020023505A2 (pt) | 2018-06-01 | 2021-03-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Composições e usos das mesmas para tratamento de doença ou condição |
JP7372237B2 (ja) | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
US11993661B2 (en) | 2018-06-18 | 2024-05-28 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof |
WO2019243636A1 (en) | 2018-06-22 | 2019-12-26 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
CA3103017A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
JP2021528988A (ja) | 2018-07-04 | 2021-10-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規の二重特異性アゴニスト4−1bb抗原結合分子 |
PE20211604A1 (es) | 2018-07-09 | 2021-08-23 | Five Prime Therapeutics Inc | Anticuerpos de union a ilt4 |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
KR20210031722A (ko) | 2018-07-11 | 2021-03-22 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
MX2021000558A (es) | 2018-07-18 | 2021-04-13 | Genentech Inc | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino. |
SG11202100373VA (en) | 2018-07-20 | 2021-02-25 | Surface Oncology Inc | Anti-cd112r compositions and methods |
CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
AU2019315226A1 (en) | 2018-08-03 | 2021-03-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
US20200047085A1 (en) | 2018-08-09 | 2020-02-13 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
BR112021002037A2 (pt) | 2018-08-10 | 2021-05-04 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação de antígeno anti-cd137 e uso da mesma |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
EP3856764A4 (en) | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
CA3113548A1 (en) | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-fap clone 212 |
JP2022511396A (ja) | 2018-10-01 | 2022-01-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd40への三価結合を伴う二重特異性抗原結合分子 |
EP3632929A1 (en) | 2018-10-02 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Antibodies and uses thereof |
SG11202102875YA (en) | 2018-10-05 | 2021-04-29 | Five Prime Therapeutics Inc | Anti-fgfr2 antibody formulations |
CN113166262A (zh) | 2018-10-11 | 2021-07-23 | 英伊布里克斯公司 | Pd-1单结构域抗体及其治疗组合物 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
CA3117856A1 (en) | 2018-10-31 | 2020-05-07 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
KR20210101235A (ko) | 2018-11-16 | 2021-08-18 | 메모리얼 슬로안 케터링 캔서 센터 | 뮤신-16에 대한 항체 및 이의 사용 방법 |
WO2020117952A2 (en) | 2018-12-05 | 2020-06-11 | Genentech, Inc. | Diagnostic methods and compositions for cancer immunotherapy |
AU2018451747A1 (en) | 2018-12-06 | 2021-06-17 | F. Hoffmann-La Roche Ag | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
JP2022514290A (ja) | 2018-12-20 | 2022-02-10 | ジェネンテック, インコーポレイテッド | 改変抗体fcおよび使用方法 |
UA128001C2 (uk) | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
CN113286822A (zh) | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | 靶向肿瘤的超激动性cd28抗原结合分子 |
MX2021007769A (es) | 2018-12-26 | 2021-09-23 | Xilio Dev Inc | Proteínas de unión anti-ctla4 enmascaradas activables. |
CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
CA3124837A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
CN113329770A (zh) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | 新型癌抗原及所述抗原的抗体 |
MA54863A (fr) | 2019-01-29 | 2021-12-08 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1) |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
JP2022521773A (ja) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | 抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬 |
KR20210138588A (ko) | 2019-03-08 | 2021-11-19 | 제넨테크, 인크. | 세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법 |
MA55296A (fr) | 2019-03-14 | 2022-03-23 | Hoffmann La Roche | Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2 |
EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
KR20220002967A (ko) | 2019-04-19 | 2022-01-07 | 제넨테크, 인크. | 항 mertk 항체 및 이의 사용 방법 |
EP3957325A4 (en) | 2019-04-19 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE |
EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
KR20220007136A (ko) | 2019-05-14 | 2022-01-18 | 제넨테크, 인크. | 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법 |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
WO2020234473A1 (en) | 2019-05-23 | 2020-11-26 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
KR20220017430A (ko) * | 2019-06-05 | 2022-02-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 절단 부위 결합 분자 |
TW202115124A (zh) | 2019-06-26 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 結合至cea之新穎抗原結合分子 |
EP3990492A1 (en) | 2019-06-27 | 2022-05-04 | F. Hoffmann-La Roche AG | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
CN114269783B (zh) | 2019-07-02 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | 结合egfrviii的单克隆抗体及其应用 |
US20220372138A1 (en) | 2019-07-05 | 2022-11-24 | Iomx Therapeutics Ag | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
CN114341187A (zh) | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | 抗突变型fgfr3抗体及其用途 |
CA3148740A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
WO2021050645A1 (en) | 2019-09-12 | 2021-03-18 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
AU2020350689A1 (en) | 2019-09-19 | 2022-03-31 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
TW202126699A (zh) | 2019-09-20 | 2021-07-16 | 美商建南德克公司 | 用於抗類胰蛋白酶抗體之投藥 |
AU2020351734A1 (en) | 2019-09-27 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
EP4045090A1 (en) | 2019-10-18 | 2022-08-24 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
KR20220092580A (ko) | 2019-11-06 | 2022-07-01 | 제넨테크, 인크. | 혈액암의 치료를 위한 진단과 치료 방법 |
JP2023501229A (ja) | 2019-11-15 | 2023-01-18 | エンテラ・エッセ・エッレ・エッレ | Tmem219抗体及びその治療的使用 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
CN114746442A (zh) | 2019-11-21 | 2022-07-12 | 恩瑟拉有限责任公司 | Igfbp3抗体及其治疗性用途 |
CN115335399A (zh) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
BR112022010627A2 (pt) | 2019-12-06 | 2022-08-16 | Juno Therapeutics Inc | Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados |
AU2020403145A1 (en) | 2019-12-13 | 2022-07-07 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
BR112022011723A2 (pt) | 2019-12-27 | 2022-09-06 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-ctla-4 e uso do mesmo |
CN113045655A (zh) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
CA3162009A1 (en) | 2020-01-09 | 2021-07-15 | F. Hoffmann-La Roche Ag | New 4-1bbl trimer-containing antigen binding molecules |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
JP2023512654A (ja) | 2020-01-31 | 2023-03-28 | ジェネンテック, インコーポレイテッド | Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法 |
WO2021155295A1 (en) | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
EP4093762A1 (en) | 2020-02-20 | 2022-11-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
EP3868396A1 (en) | 2020-02-20 | 2021-08-25 | Enthera S.R.L. | Inhibitors and uses thereof |
JP2023516941A (ja) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗cd137コンストラクト、多重特異性抗体及びその使用 |
KR20220148209A (ko) | 2020-02-28 | 2022-11-04 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물 및 그 용도 |
KR20220152262A (ko) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | 항-인터루킨-33 항체 및 이의 용도 |
AU2021236660A1 (en) | 2020-03-19 | 2022-08-18 | Genentech, Inc. | Isoform-selective anti-TGF-beta antibodies and methods of use |
US20230125415A1 (en) | 2020-03-23 | 2023-04-27 | Genentech, Inc. | Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia |
JP2023518815A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Il6アンタゴニストによるcovid-19肺炎を含む肺炎の治療方法 |
JP2023518812A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ |
BR112022018847A2 (pt) | 2020-03-24 | 2022-11-22 | Genentech Inc | Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
JP2023522930A (ja) | 2020-04-24 | 2023-06-01 | ジェネンテック, インコーポレイテッド | 抗CD79b免疫抱合体の使用方法 |
CA3172880A1 (en) | 2020-04-27 | 2021-11-04 | Sotirios Tsimikas | Isoform-independent antibodies to lipoprotein(a) |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
CN116963782A (zh) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | 包含抗trop-2抗体的抗体药物偶联物 |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
MX2022015376A (es) | 2020-06-02 | 2023-04-14 | Dynamicure Biotechnology Llc | Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas. |
CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
CN115698719A (zh) | 2020-06-12 | 2023-02-03 | 基因泰克公司 | 用于癌症免疫疗法的方法和组合物 |
AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists |
JP2023538716A (ja) | 2020-06-19 | 2023-09-11 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3及びcd19に結合する抗体 |
WO2021259890A1 (en) | 2020-06-23 | 2021-12-30 | F. Hoffmann-La Roche Ag | Agonistic cd28 antigen binding molecules targeting her2 |
CN115916830A (zh) | 2020-06-25 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 抗cd3/抗cd28双特异性抗原结合分子 |
US20240010720A1 (en) | 2020-07-06 | 2024-01-11 | Iomx Therapeutics Ag | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
WO2022008468A1 (en) | 2020-07-07 | 2022-01-13 | F. Hoffmann-La Roche Ag | Alternative surfactants as stabilizers for therapeutic protein formulations |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2022026763A1 (en) | 2020-07-29 | 2022-02-03 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
CN116568824A (zh) | 2020-08-03 | 2023-08-08 | 基因泰克公司 | 淋巴瘤的诊断和治疗方法 |
EP4192868A1 (en) | 2020-08-05 | 2023-06-14 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
IL300260A (en) | 2020-08-07 | 2023-03-01 | Genentech Inc | FLT3 ligand fusion proteins and methods of use |
CN116615452A (zh) | 2020-08-14 | 2023-08-18 | Ac免疫有限公司 | 人源化抗tdp-43结合分子及其用途 |
WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
AU2021343834A1 (en) | 2020-09-15 | 2023-04-13 | Bayer Aktiengesellschaft | Novel anti-A2AP antibodies and uses thereof |
JP2023541921A (ja) | 2020-09-17 | 2023-10-04 | ジェネンテック, インコーポレイテッド | Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果 |
CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
CA3190782A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors |
EP4232475A1 (en) | 2020-10-20 | 2023-08-30 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
CA3173151A1 (en) | 2020-11-03 | 2022-05-12 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
WO2022098628A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
JP2023548064A (ja) | 2020-11-04 | 2023-11-15 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体及び抗cd79b抗体薬物コンジュゲートによる処置のための投与 |
US20220162329A1 (en) | 2020-11-04 | 2022-05-26 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
CN117916261A (zh) | 2020-11-16 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 与靶向fap的cd40激动剂的组合疗法 |
TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
AU2022206061A1 (en) | 2021-01-06 | 2023-07-06 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
WO2022162587A1 (en) | 2021-01-27 | 2022-08-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
AU2022212599A1 (en) | 2021-01-28 | 2023-08-17 | Universität Ulm | Method and means for modulating b-cell mediated immune responses |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
CN117120084A (zh) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | 用于调节b细胞介导的免疫应答的方法和手段 |
EP4291226A1 (en) | 2021-02-09 | 2023-12-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibodies targeting the spike protein of coronaviruses |
AU2022220611A1 (en) | 2021-02-09 | 2023-08-24 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
CA3208365A1 (en) | 2021-02-15 | 2022-08-18 | Chantal KUHN | Cell therapy compositions and methods for modulating tgf-b signaling |
EP4298123A2 (en) | 2021-02-26 | 2024-01-03 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
WO2022187272A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
EP4301467A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
CN117440832A (zh) | 2021-03-03 | 2024-01-23 | 索伦托药业有限公司 | 包括抗bcma抗体的抗体-药物缀合物 |
US20240141048A1 (en) | 2021-03-05 | 2024-05-02 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
CA3213599A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
CN117616041A (zh) | 2021-03-25 | 2024-02-27 | 当康生物技术有限责任公司 | 抗-igfbp7构建体及其用途 |
CA3215274A1 (en) | 2021-03-30 | 2022-10-06 | Bayer Aktiengesellschaft | Anti-sema3a antibodies and uses thereof |
AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
IL307821A (en) | 2021-04-30 | 2023-12-01 | Hoffmann La Roche | Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody |
JP2024517535A (ja) | 2021-04-30 | 2024-04-23 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗cd20/抗cd3二重特異性抗体と抗cd79b抗体薬物コンジュゲートを用いた併用治療の投与 |
IL308351A (en) | 2021-05-12 | 2024-01-01 | Genentech Inc | Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma |
KR20240007928A (ko) | 2021-05-14 | 2024-01-17 | 제넨테크, 인크. | Trem2의 효능제 |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
EP4351582A1 (en) | 2021-06-09 | 2024-04-17 | F. Hoffmann-La Roche AG | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
IL308597A (en) | 2021-06-11 | 2024-01-01 | Genentech Inc | A method for treating chronic obstructive pulmonary disease with an ST2 antagonist |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022263638A1 (en) | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-CTLA-4 antibodies |
IL309115A (en) | 2021-06-25 | 2024-02-01 | Chugai Pharmaceutical Co Ltd | Anti-CTLA-4 antibodies |
EP4367139A1 (en) | 2021-07-08 | 2024-05-15 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
KR20240058075A (ko) | 2021-07-14 | 2024-05-03 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | Cd40을 특이적으로 식별하는 항체 및 이의 응용 |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
KR20240046524A (ko) | 2021-08-07 | 2024-04-09 | 제넨테크, 인크. | 미만성 거대 b-세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법 |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
CN117858905A (zh) | 2021-08-19 | 2024-04-09 | 豪夫迈·罗氏有限公司 | 多价抗变体fc区抗体及使用方法 |
KR20240049296A (ko) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | 타우 병증을 치료하는 방법 |
WO2023034750A1 (en) | 2021-08-30 | 2023-03-09 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
AU2022345251A1 (en) | 2021-09-17 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
JPWO2023058723A1 (zh) | 2021-10-08 | 2023-04-13 | ||
CA3236417A1 (en) | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
AU2022389969A1 (en) | 2021-11-16 | 2024-05-02 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
CA3235206A1 (en) | 2021-11-16 | 2023-05-25 | Davide BASCO | Novel molecules for therapy and diagnosis |
CA3240565A1 (en) | 2021-12-17 | 2023-06-22 | Wenfeng Xu | Anti-ox40 antibodies and methods of use |
CA3240585A1 (en) | 2021-12-17 | 2023-06-22 | Wenfeng Xu | Anti-ox40 antibodies, multispecific antibodies and methods of use |
AU2022423749A1 (en) | 2021-12-20 | 2024-06-13 | F. Hoffmann-La Roche Ag | Agonistic ltbr antibodies and bispecific antibodies comprising them |
AR128222A1 (es) | 2022-01-07 | 2024-04-10 | Johnson & Johnson Entpr Innovation Inc | MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023192827A1 (en) | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to hiv-1 env and their use |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2023186756A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Interferon gamma variants and antigen binding molecules comprising these |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
TW202408562A (zh) | 2022-04-13 | 2024-03-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
TW202406934A (zh) | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | 抗Ly6E抗體、免疫結合物及其用途 |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
US11807689B1 (en) * | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
US20240132622A1 (en) | 2022-07-22 | 2024-04-25 | Bristol-Myers Squibb Company | Antibodies Binding to Human PAD4 and Uses Thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024044779A2 (en) | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
WO2024097741A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
WO2024102734A1 (en) | 2022-11-08 | 2024-05-16 | Genentech, Inc. | Compositions and methods of treating childhood onset idiopathic nephrotic syndrome |
WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
WO2024108053A1 (en) | 2022-11-17 | 2024-05-23 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US20030003097A1 (en) * | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
WO2003011878A2 (en) * | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
Family Cites Families (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097A (en) | 1850-02-19 | Elevating- and lowering carriage-tops | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0365685B1 (en) | 1988-03-30 | 1995-01-18 | Toray Industries, Inc. | Freeze-dried composition comprising a horseradish peroxidase-labelled Fab' fragment of an anti-human interferon-beta monclonal antibody and trehalose; EIA kit containing the composition |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0556285A4 (en) | 1990-11-05 | 1993-10-27 | Bristol-Myers Squibb Company | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US20030180290A1 (en) * | 1995-06-07 | 2003-09-25 | Idec Pharmaceuticals Corporation | Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies |
EP1516628B1 (en) | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
WO1998004281A1 (en) | 1996-07-26 | 1998-02-05 | Smithkline Beecham Corpration | Improved method of treating immune cell mediated systemic diseases |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
ES2337091T3 (es) | 1996-11-27 | 2010-04-20 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina. |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | 抗体製剤 |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US20040191256A1 (en) * | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
BR9909382A (pt) * | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
DK2180007T4 (da) * | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
PT1308455E (pt) | 1998-05-06 | 2006-08-31 | Genentech Inc | Composicao compreendendo anticorpos anti-her2 |
EA004107B1 (ru) | 1998-08-11 | 2003-12-25 | Айдек Фармацевтикалс Корпорэйшн | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 |
AU5565299A (en) | 1998-08-17 | 2000-03-06 | California Institute Of Technology | Devices and methods for analysis of non-ionic solutes |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
AU761844C (en) | 1998-11-09 | 2004-09-23 | F. Hoffmann-La Roche Ag | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
ATE454166T1 (de) * | 1998-11-09 | 2010-01-15 | Biogen Idec Inc | Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
US7074403B1 (en) | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
CN101264324A (zh) | 1999-07-12 | 2008-09-17 | 杰南技术公司 | 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答 |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
CA2378646A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
CN1169952C (zh) | 1999-10-10 | 2004-10-06 | 中国医学科学院中国协和医科大学血液学研究所血液病医院 | 抗cd20单克隆抗体的重链和轻链可变区基因及其应用 |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
EP1229935A1 (en) * | 1999-11-08 | 2002-08-14 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
AU2001260153B2 (en) | 2000-03-24 | 2006-08-17 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex |
AU8729101A (en) * | 2000-03-31 | 2001-10-15 | Idec Pharma Corp | Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma |
JP2003531178A (ja) | 2000-04-25 | 2003-10-21 | アイデック ファーマスーティカルズ コーポレイション | 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与 |
EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
IL153764A0 (en) | 2000-07-12 | 2003-07-06 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
JP4795619B2 (ja) * | 2000-07-31 | 2011-10-19 | バイオレックス・セラピューティクス インコーポレイテッド | ウキクサにおける生物学的に活性なポリペプチド類の発現 |
DE10043452A1 (de) | 2000-09-04 | 2002-03-14 | Basf Ag | Formkörper mit einer tonmineralischen Beschichtung |
JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | B細胞枯渇抗体/免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
AU2002213357A1 (en) * | 2000-10-20 | 2002-05-06 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2436180C (en) * | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
US20030211107A1 (en) | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
WO2002062850A2 (en) | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
ATE507839T1 (de) | 2001-04-02 | 2011-05-15 | Genentech Inc | Kombinationstherapie |
WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
EP2298809A3 (en) * | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
WO2003024388A2 (en) | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
KR100988949B1 (ko) * | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP2359685B1 (en) | 2001-12-27 | 2013-12-04 | GlycoFi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
EP1485492B1 (en) | 2002-03-19 | 2011-12-21 | Stichting Dienst Landbouwkundig Onderzoek | Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants |
CN1283662C (zh) | 2002-03-21 | 2006-11-08 | 伊莱利利公司 | 拮抗性抗hFAS配基人类抗体及其片段 |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
US20050031613A1 (en) * | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
EP1500400A4 (en) * | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
US20040132097A1 (en) * | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
PT1539966E (pt) | 2002-09-12 | 2010-09-14 | Greenovation Biotech Gmbh | Método de produção de proteínas |
KR20090088973A (ko) | 2002-10-17 | 2009-08-20 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
AU2003298799A1 (en) * | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
SI2289936T1 (sl) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
CA2507880A1 (en) * | 2002-12-16 | 2004-07-22 | Genentech, Inc. | Transgenic mice expressing human cd20 and/or cd16 |
WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2004063351A2 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
EP2264151B1 (en) | 2003-01-22 | 2016-04-20 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
EP1585768A2 (en) * | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
EP1603948A1 (en) * | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
WO2004091657A2 (en) * | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
PT1631313E (pt) | 2003-06-05 | 2015-07-02 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
RU2370775C2 (ru) * | 2003-07-29 | 2009-10-20 | Дженентек, Инк. | Анализ нейтрализующих антител и его применение |
AU2004280333A1 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
RU2006110036A (ru) | 2003-08-29 | 2006-08-10 | Дженентек, Инк. (Us) | Лечение глазных расстройств анти-cd20 |
LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
US20050191297A1 (en) * | 2003-12-19 | 2005-09-01 | Genentech, Inc. | Detection of CD20 in transplant rejection |
CA2549122A1 (en) | 2003-12-19 | 2005-07-07 | Genentech, Inc. | Detection of cd20 in therapy of autoimmune diseases |
KR20070001932A (ko) | 2003-12-23 | 2007-01-04 | 리나트 뉴로사이언스 코퍼레이션 | 작용물질 항 티알케이씨 항체 및 그의 사용 방법 |
US20050288491A1 (en) | 2004-02-17 | 2005-12-29 | Wilson David S | Super-humanized antibodies against respiratory syncytial virus |
US20060099662A1 (en) | 2004-04-16 | 2006-05-11 | Genentech, Inc. | Assay for antibodies |
RU2006140374A (ru) | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | Лечение нарушений |
WO2005113003A2 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting b cell depletion |
SG175659A1 (en) | 2004-05-05 | 2011-11-28 | Genentech Inc | Preventing autoimmune disease by using an anti-cd20 antibody |
JP2007538258A (ja) | 2004-05-15 | 2007-12-27 | ジェネンテック・インコーポレーテッド | 標的分子に結合親和性を有する分子を検出するためのクロススクリーニングシステムと方法 |
AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
MXPA06014067A (es) | 2004-06-04 | 2007-02-15 | Genentech Inc | Metodo para tratar lupus. |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
EP1781378A2 (en) | 2004-07-22 | 2007-05-09 | Genentech, Inc. | Method of treating sjögren's syndrome |
EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1802660A2 (en) * | 2004-09-08 | 2007-07-04 | Genentech, Inc. | Methods of using death receptor ligands and cd20 antibodies |
BRPI0515615A (pt) * | 2004-09-08 | 2008-07-29 | Genentech Inc | métodos para tratar células cancerosas e doença imune relacionada |
US7572456B2 (en) * | 2004-09-13 | 2009-08-11 | Macrogenics, Inc. | Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof |
KR20070100228A (ko) | 2004-10-05 | 2007-10-10 | 제넨테크, 인크. | 혈관염의 치료 방법 |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
PE20061075A1 (es) * | 2004-12-17 | 2006-11-15 | Genentech Inc | Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior |
EP1833970A2 (en) | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
JP2008526998A (ja) | 2005-01-13 | 2008-07-24 | ジェネンテック・インコーポレーテッド | 治療方法 |
DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
EP1874350A2 (en) | 2005-04-22 | 2008-01-09 | Genentech, Inc. | Method for treating dementia or alzheimer's disease with a cd20 antibody |
WO2006125140A2 (en) | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
KR20080046135A (ko) | 2005-05-20 | 2008-05-26 | 제넨테크, 인크. | 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리 |
KR20080032065A (ko) * | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
CA2619298C (en) * | 2005-08-26 | 2017-07-04 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US20070136826A1 (en) | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
US7708944B1 (en) | 2006-06-13 | 2010-05-04 | Research Foundation Of State University Of New York | Ultra-sensitive, portable capillary sensor |
JP2010527325A (ja) | 2007-04-02 | 2010-08-12 | ジェネンテック, インコーポレイテッド | B細胞アンタゴニストに応答する関節リウマチを予測するバイオマーカー |
WO2008157282A1 (en) | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
LT3327026T (lt) | 2007-07-09 | 2019-11-11 | Genentech Inc | Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu |
KR100898362B1 (ko) | 2007-07-10 | 2009-05-18 | 주식회사 그리폰 | 다목적 신발 |
AU2008295140A1 (en) | 2007-09-05 | 2009-03-12 | F. Hoffmann-La Roche Ag | Combination therapy with type I and type II anti-CD20 antibodies |
GB0718684D0 (en) | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
US20090214561A1 (en) | 2007-09-24 | 2009-08-27 | David Robert Close | Treatment method |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
US20090110688A1 (en) | 2007-10-24 | 2009-04-30 | Georg Fertig | Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
ES2666170T3 (es) | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
US20090162351A1 (en) | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
AU2008342956A1 (en) | 2007-12-21 | 2009-07-09 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
UA101487C2 (en) | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
JP2011507870A (ja) | 2007-12-21 | 2011-03-10 | ジェネンテック, インコーポレイテッド | 抗cd20抗体の結晶化 |
EP2268310B1 (en) | 2008-03-25 | 2016-07-20 | Roche Glycart AG | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
WO2009134738A1 (en) | 2008-04-29 | 2009-11-05 | Genentech, Inc. | Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody |
US8021850B2 (en) | 2008-07-14 | 2011-09-20 | Ribo Guo | Universal tandem solid-phases based immunoassay |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
CN102281903B (zh) | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
MX2011005056A (es) | 2008-11-17 | 2011-05-31 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
JP2013501741A (ja) | 2009-08-14 | 2013-01-17 | ロシュ グリクアート アーゲー | アフコシル化cd20抗体とフルダラビン及び/又はミトキサントロンの併用療法 |
BR112012004777A2 (pt) | 2009-09-03 | 2019-09-24 | Genentech Inc | métodos para tratar diagnósticar e monitorar artrite reumatoide |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011131749A1 (en) | 2010-04-23 | 2011-10-27 | Glaxo Group Limited | New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases |
KR20130045914A (ko) | 2010-08-03 | 2013-05-06 | 에프. 호프만-라 로슈 아게 | 만성 림프구성 백혈병(cll) 생체지표 |
TW201208703A (en) | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
RU2013140975A (ru) | 2011-02-28 | 2015-04-10 | Дженентек, Инк. | Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток |
US8592156B2 (en) | 2011-08-08 | 2013-11-26 | Roche Molecular Systems, Inc. | Predicting response to anti-CD20 therapy in DLBCL patients |
US20140172120A1 (en) | 2012-09-06 | 2014-06-19 | Freedom Innovations, Llc | Method and system for a prosthetic device with multiple levels of functionality enabled through multiple control systems |
EP3919079A1 (en) | 2012-09-07 | 2021-12-08 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
-
2004
- 2004-11-05 LT LTEP10185313.3T patent/LT2380911T/lt unknown
- 2004-11-05 DK DK04798998.3T patent/DK1692182T3/da active
- 2004-11-05 PT PT10185340T patent/PT2348051T/pt unknown
- 2004-11-05 US US10/981,738 patent/US9296820B2/en active Active
- 2004-11-05 PL PL10185313T patent/PL2380911T3/pl unknown
- 2004-11-05 KR KR1020127020631A patent/KR101364858B1/ko active IP Right Grant
- 2004-11-05 ME MEP-2016-202A patent/ME02332B/me unknown
- 2004-11-05 RS RSP-2010/0225A patent/RS51334B/en unknown
- 2004-11-05 TR TR2019/03329T patent/TR201903329T4/tr unknown
- 2004-11-05 BR BR122020013239-6A patent/BR122020013239B1/pt active IP Right Grant
- 2004-11-05 ES ES10185340T patent/ES2708095T3/es active Active
- 2004-11-05 PL PL04798998T patent/PL1692182T3/pl unknown
- 2004-11-05 DK DK10185313.3T patent/DK2380911T3/en active
- 2004-11-05 SG SG10202008722QA patent/SG10202008722QA/en unknown
- 2004-11-05 EP EP10185277.0A patent/EP2380910B1/en active Active
- 2004-11-05 RS RS20190202A patent/RS58420B1/sr unknown
- 2004-11-05 LT LTEP10185340.6T patent/LT2348051T/lt unknown
- 2004-11-05 KR KR1020067011070A patent/KR101220691B1/ko active Protection Beyond IP Right Term
- 2004-11-05 ES ES10185277.0T patent/ES2550311T3/es active Active
- 2004-11-05 PL PL10185340T patent/PL2348051T3/pl unknown
- 2004-11-05 DK DK10185340.6T patent/DK2348051T3/en active
- 2004-11-05 SI SI200432461T patent/SI2348051T1/sl unknown
- 2004-11-05 EA EA202091901A patent/EA202091901A1/ru unknown
- 2004-11-05 DK DK09004064.3T patent/DK2077282T3/en active
- 2004-11-05 CA CA2544865A patent/CA2544865C/en active Active
- 2004-11-05 EA EA201100128A patent/EA025962B1/ru active Protection Beyond IP Right Term
- 2004-11-05 ES ES09004064.3T patent/ES2615507T3/es active Active
- 2004-11-05 SG SG10201504094SA patent/SG10201504094SA/en unknown
- 2004-11-05 CN CN201510181109.4A patent/CN104829719A/zh active Pending
- 2004-11-05 CN CN200480039946.3A patent/CN1902231B/zh active Active
- 2004-11-05 HU HUE09004064A patent/HUE031632T2/en unknown
- 2004-11-05 ES ES10185313.3T patent/ES2672640T3/es active Active
- 2004-11-05 PT PT101852770T patent/PT2380910E/pt unknown
- 2004-11-05 EP EP09004064.3A patent/EP2077282B1/en active Active
- 2004-11-05 HU HUE10185340A patent/HUE042914T2/hu unknown
- 2004-11-05 ME MEP-2019-49A patent/ME03330B/me unknown
- 2004-11-05 EP EP10185340.6A patent/EP2348051B1/en active Active
- 2004-11-05 PL PL10185277T patent/PL2380910T3/pl unknown
- 2004-11-05 MX MXPA06004836A patent/MXPA06004836A/es active IP Right Grant
- 2004-11-05 SG SG201001348-0A patent/SG160348A1/en unknown
- 2004-11-05 SI SI200432374A patent/SI2077282T1/sl unknown
- 2004-11-05 DE DE602004026470T patent/DE602004026470D1/de active Active
- 2004-11-05 NO NO20220263A patent/NO347530B1/no unknown
- 2004-11-05 NZ NZ547589A patent/NZ547589A/en unknown
- 2004-11-05 RS RS20150731A patent/RS54450B1/en unknown
- 2004-11-05 TR TR2018/09892T patent/TR201809892T4/tr unknown
- 2004-11-05 ES ES04798998T patent/ES2341009T3/es active Active
- 2004-11-05 NO NO20210499A patent/NO346533B1/no unknown
- 2004-11-05 ME MEP-2010-225A patent/ME01775B/me unknown
- 2004-11-05 LT LTEP09004064.3T patent/LT2077282T/lt unknown
- 2004-11-05 SI SI200431421T patent/SI1692182T1/sl unknown
- 2004-11-05 RS RS20180868A patent/RS57466B1/sr unknown
- 2004-11-05 BR BRPI0416262-5A patent/BRPI0416262B1/pt active IP Right Grant
- 2004-11-05 SI SI200432272T patent/SI2380910T1/sl unknown
- 2004-11-05 WO PCT/IB2004/003896 patent/WO2005044859A2/en active Application Filing
- 2004-11-05 PL PL09004064T patent/PL2077282T3/pl unknown
- 2004-11-05 UA UAA200606108A patent/UA91823C2/ru unknown
- 2004-11-05 PT PT04798998T patent/PT1692182E/pt unknown
- 2004-11-05 AU AU2004287643A patent/AU2004287643C1/en active Active
- 2004-11-05 AT AT04798998T patent/ATE463513T1/de active
- 2004-11-05 CN CN201110285834.8A patent/CN102373215B/zh active Active
- 2004-11-05 JP JP2006538995A patent/JP4653109B2/ja active Active
- 2004-11-05 MX MX2013012567A patent/MX337587B/es unknown
- 2004-11-05 RS RS20170173A patent/RS55723B1/sr unknown
- 2004-11-05 SI SI200432440T patent/SI2380911T1/en unknown
- 2004-11-05 EP EP04798998A patent/EP1692182B1/en active Active
- 2004-11-05 NZ NZ588860A patent/NZ588860A/en unknown
- 2004-11-05 EA EA200600905A patent/EA015009B1/ru active Protection Beyond IP Right Term
- 2004-11-05 CN CN201110285833.3A patent/CN102373214B/zh active Active
- 2004-11-05 PT PT90040643T patent/PT2077282T/pt unknown
- 2004-11-05 DK DK10185277.0T patent/DK2380910T3/en active
- 2004-11-05 PT PT101853133T patent/PT2380911T/pt unknown
- 2004-11-05 HU HUE10185313A patent/HUE038955T2/hu unknown
- 2004-11-05 EP EP10185313.3A patent/EP2380911B1/en active Active
- 2004-11-05 KR KR1020117027731A patent/KR101364902B1/ko active IP Right Grant
- 2004-11-05 HU HUE10185277A patent/HUE026669T2/en unknown
- 2004-11-05 EA EA201300481A patent/EA036531B1/ru unknown
-
2006
- 2006-05-01 IL IL175367A patent/IL175367A/en active Protection Beyond IP Right Term
- 2006-05-04 TN TNP2006000126A patent/TNSN06126A1/en unknown
- 2006-05-19 NO NO20062289A patent/NO341893B1/no active Protection Beyond IP Right Term
- 2006-05-24 MA MA29059A patent/MA31040B1/fr unknown
- 2006-06-02 ZA ZA200604547A patent/ZA200604547B/en unknown
- 2006-06-02 EC EC2006006603A patent/ECSP066603A/es unknown
-
2007
- 2007-07-18 HK HK07107722.3A patent/HK1100005A1/zh unknown
- 2007-07-18 HK HK12108387.0A patent/HK1167682A1/zh unknown
- 2007-07-18 HK HK12108384.3A patent/HK1167681A1/zh unknown
- 2007-08-17 US US11/889,975 patent/US8883980B2/en active Active
-
2009
- 2009-11-26 JP JP2009268995A patent/JP2010081940A/ja not_active Withdrawn
-
2010
- 2010-05-27 HR HR20100303T patent/HRP20100303T1/hr unknown
- 2010-07-02 CY CY20101100610T patent/CY1110301T1/el unknown
- 2010-08-02 IL IL207347A patent/IL207347A/en active IP Right Grant
- 2010-12-15 CR CR11848A patent/CR11848A/es unknown
-
2012
- 2012-07-23 JP JP2012162906A patent/JP6125770B2/ja active Active
-
2014
- 2014-06-02 IL IL232954A patent/IL232954A/en active IP Right Grant
- 2014-10-19 IL IL235172A patent/IL235172A0/en unknown
-
2015
- 2015-01-09 LU LU92632C patent/LU92632I2/xx unknown
- 2015-01-15 CY CY2015001C patent/CY2015001I1/el unknown
- 2015-04-01 JP JP2015075370A patent/JP6235521B2/ja active Active
- 2015-07-31 US US14/815,604 patent/US20160075794A1/en not_active Abandoned
- 2015-07-31 US US14/815,562 patent/US20160075793A1/en not_active Abandoned
- 2015-07-31 US US14/815,583 patent/US20160076009A1/en not_active Abandoned
- 2015-11-23 FR FR15C0076C patent/FR15C0076I2/fr active Active
- 2015-12-23 HR HRP20151418TT patent/HRP20151418T1/hr unknown
-
2016
- 2016-02-03 HK HK16101265.8A patent/HK1213574A1/zh unknown
- 2016-02-18 CY CY2016004C patent/CY2016004I1/el unknown
- 2016-03-03 BE BE2016C008C patent/BE2016C008I2/fr unknown
- 2016-03-10 LT LTPA2016006C patent/LTC2380910I2/lt unknown
- 2016-03-14 LU LU93001C patent/LU93001I2/xx unknown
- 2016-03-16 NL NL300801C patent/NL300801I2/nl unknown
- 2016-03-23 HU HUS1600013C patent/HUS1600013I1/hu unknown
-
2017
- 2017-03-09 HR HRP20170398TT patent/HRP20170398T2/hr unknown
- 2017-03-14 CY CY20171100324T patent/CY1118719T1/el unknown
- 2017-09-07 JP JP2017172375A patent/JP2018027088A/ja active Pending
- 2017-12-13 NO NO20171989A patent/NO346167B1/no unknown
-
2018
- 2018-05-22 CY CY20181100537T patent/CY1120252T1/el unknown
- 2018-07-25 HR HRP20181204TT patent/HRP20181204T1/hr unknown
-
2019
- 2019-01-31 CY CY20191100144T patent/CY1121206T1/el unknown
- 2019-02-19 HR HRP20190333TT patent/HRP20190333T1/hr unknown
-
2020
- 2020-02-11 US US16/787,936 patent/US20210002382A1/en not_active Abandoned
-
2021
- 2021-04-14 EC ECSENADI202123271A patent/ECSP21023271A/es unknown
-
2022
- 2022-08-24 NO NO20220904A patent/NO347800B1/no unknown
- 2022-08-24 US US17/822,105 patent/US20230212303A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US20030003097A1 (en) * | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
WO2003011878A2 (en) * | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
Non-Patent Citations (2)
Title |
---|
MARIA J.POLYAK ET AL: "Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes;heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure", 《BLOOD》 * |
MARK S.CRAGG ET AL: "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts", 《BLOOD》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102373215B (zh) | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 | |
CN103204935B (zh) | 具有改变的细胞信号传导活性的修饰的抗原结合分子 | |
CN101146909A (zh) | 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1167682 Country of ref document: HK |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Schlieren - Zurich, Switzerland Applicant after: Glycart Biotechnology AG Address before: Schlieren - Zurich, Switzerland Applicant before: Glycart Biotechnology AG |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GLYCART BIOTECHNOLOGY AG TO: GLYCART BIOTECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1167682 Country of ref document: HK |